Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 185 Results

Title
Intervention Indication Therapeutic Area Year Actions
Givinostat for Duchenne muscular dystrophy Givinostat Duchenne muscular dystrophy (DMD) Genetic Disorders , Musculoskeletal System 2023 View  |  Download
Golimumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years Golimumab Ulcerative colitis Gastroenterology 2023 View  |  Download
Human C1-esterase inhibitor (subcutaneous injection) for preventing hereditary angioedema Human C1 esterase inhibitor (Berinert) Hereditary angioedema (HAE) Genetic Disorders , Immunology 2023 View  |  Download
Hydromethylthionine mesylate for Alzheimer's disease Hydromethylthionine mesylate (LMTX;TRx-0237) Alzheimer's disease Neurology 2023 View  |  Download
I-131-Apamistamab for acute myeloid leukaemia I-131-Apamistamab (Iomab-B) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2023 View  |  Download
IcoSema for treating adults with type 2 diabetes IcoSema (NN1535) Type 2 diabetes Endocrine Nutritional and Metabolic Disorders 2023 View  |  Download
Imlunestrant with or without abemaciclib for treating ER-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine therapy Imlunestrant Breast cancer Breast Cancer 2023 View  |  Download
Invimestrocel for Acute ischaemic stroke Multistem(PF05285401;HLCM05;invimestrocel) Acute ischaemic stroke Cardiovascular System 2023 View  |  Download
Iptacopan for treating complement 3 glomerulopathy Iptacopan Complement 3 glomerulopathy Immunology , Neurology 2023 View  |  Download
Isatuximab induction therapy with bortezomib, lenalidomide and dexamethasone for previously untreated multiple myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2023 View  |  Download
1 2 6 7 8 9 10 18 19
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications